Catalyst
Slingshot members are tracking this event:
Evoke (EVOK) to Submit New Drug Application in Q1 2018 Under Accelerated Pathway for Gitmoti in Relief of Symptoms Associated with Acute and Recurrent Diabetic Gastroparesis in Adult Women
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| EVOK |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 05, 2018
Occurred Source:
http://investor.evokepharma.com/news-releases/news-release-details/fda-approves-pdufa-fee-waiver-gimotitm-new-drug-application
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
New Drug Application, Accelerated Pathway, Gitmoti, Acute, Recurrent, Diabetic Gastroparesis, Adult Women
